CardiacDevices @CardiacDevices - Twitter Profile

CardiacDevices @CardiacDevices

almost 7 years ago

https://t.co/2RHgCHHMzt #daxing #airport on #google #maps #china

0

CardiacDevices retweeted

Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) @Basalus

almost 7 years ago

What is the lesion? Where is the lesion? #ECG

4

2

3

1

0

CardiacDevices retweeted

Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) @Basalus

almost 7 years ago

37 years old male feeling #dizzy

3

1

2

0

CardiacDevices @CardiacDevices

almost 8 years ago

#nextlevelcrt

Abbott Cardiovascular

@AbbottCardio

almost 8 years ago

Why not turn on the next level of cardiac resynchronization therapy with MultiPoint™ Pacing and SyncAV™ CRT technology? See how they work. #NextLevelCRT Learn more and Important Safety Information: https://t.co/Q88R2OiFlJ

0

10

4

0

Who to follow

Cardiac Physiology RFT

@CardiacRFT

Keep up to date with the latest activities of the Cardiac Physiology Team at Rotherham NHS Foundation Trust.

Rui Providência

@rui_providencia

Cardiac Electrophysiologist/Cardiologist and Professor of Cardiovascular Epidemiology and Evidence Synthesis. Musician. AuDHD.

Beth Jackson

@LipidCNS

Clinical Nurse Specialist, Lipid Specialist, preventive cardiology with Cardio Texas, BOD of National Lipid Assn

CardiacDevices retweeted

Francisco Sampaio @Falmeidasampaio

almost 8 years ago

MITRA-FR: no difference in death or rehospitalization for HF in patients with severe secondary MR treated with Mitraclip. Will we continue to perform this procedure? #ESCCongress ⁦@escardio⁩

Falmeidasampaio's tweet photo. MITRA-FR: no difference in death or rehospitalization for HF in patients with severe secondary MR treated with Mitraclip. Will we continue to perform this procedure? #ESCCongress ⁦@escardio⁩ https://t.co/VqeevEEpz0

5

44

38

0

CardiacDevices retweeted

European Society of Cardiology

@escardio

almost 8 years ago · Munich

DR. Rioufil-FUTURE Trial: No difference in Primary endpoint death, MI, stroke in FFR guided vs Angio guided strategy in stable angina. Interestingly high all cause death in FFR group driven by complex coronary anatomy! #ESCCongress

escardio's tweet photo. DR. Rioufil-FUTURE Trial: No difference in Primary endpoint death, MI, stroke in FFR guided vs Angio guided strategy in stable angina. Interestingly high all cause death in FFR group driven by complex coronary anatomy! #ESCCongress https://t.co/WIxhuy8Pmt

1

63

46

1

0

CardiacDevices retweeted

NEJM

@NEJM

almost 8 years ago

MARINER: Outpatient rivaroxaban for six weeks after discharge from the hospital had no significant effect on the risk of VTE as compared with placebo. https://t.co/Tmfky8yxVq #ESCCongress #VisualAbstract

NEJM's tweet photo. MARINER: Outpatient rivaroxaban for six weeks after discharge from the hospital had no significant effect on the risk of VTE as compared with placebo. https://t.co/Tmfky8yxVq #ESCCongress #VisualAbstract https://t.co/Zl56zl96Vj

2

283

231

8

0

CardiacDevices @CardiacDevices

almost 8 years ago

will we see more patients with #pace and #ablate strategy?

Giulio Conte @GiulioConteMD

almost 8 years ago

Major findings of APAF-CRT trial presented at #ESCCongress by dr Brignole: patients with permanent AF and narrow QRS undergoing CRT plus AV junctional ablation benefit significantly in terms of reduction of death for HF, hospitalization for HF and worsening HF.

GiulioConteMD's tweet photo. Major findings of APAF-CRT trial presented at #ESCCongress by dr Brignole: patients with permanent AF and narrow QRS undergoing CRT plus AV junctional ablation benefit significantly in terms of reduction of death for HF, hospitalization for HF and worsening HF. https://t.co/qMnX7pJuyO

3

76

49

1

0

CardiacDevices retweeted

Eric Topol

@EricTopol

almost 8 years ago

Aspirin, for decades, was regarded as the "go to" primary prevention drug vs heart disease. Here the 1st of 2 randomized trials today to question that #ESCCongress https://t.co/euUYy8Uvbo @TheLancet

EricTopol's tweet photo. Aspirin, for decades, was regarded as the "go to" primary prevention drug vs heart disease. Here the 1st of 2 randomized trials today to question that #ESCCongress https://t.co/euUYy8Uvbo @TheLancet https://t.co/hrREOExMgp

28

545

357

30

0

CardiacDevices retweeted

NEJM

@NEJM

almost 8 years ago

SCOT HEART: Patients with chest pain assigned to coronary CT angiography have lower rate of CHD death or nonfatal MI at five years than those who didn’t receive CTA. https://t.co/ePNo95xFYx #ESCCongress

NEJM's tweet photo. SCOT HEART: Patients with chest pain assigned to coronary CT angiography have lower rate of CHD death or nonfatal MI at five years than those who didn’t receive CTA. https://t.co/ePNo95xFYx #ESCCongress https://t.co/wEfmJrzeU7

12

477

348

14

0

CardiacDevices retweeted

NEJM

@NEJM

almost 8 years ago

POET Trial: Changing to oral antibiotic treatment in stabilized patients with left-sided endocarditis noninferior to continued IV antibiotic tx. https://t.co/JyBvfj51YH #ESCCongress

NEJM's tweet photo. POET Trial: Changing to oral antibiotic treatment in stabilized patients with left-sided endocarditis noninferior to continued IV antibiotic tx. https://t.co/JyBvfj51YH #ESCCongress

13

434

384

20

0

CardiacDevices retweeted

C. Michael Gibson MD

@CMichaelGibson

almost 8 years ago

COMMANDER HF Trial: In pts w/ recent worsening HF w/ red. EF & CAD but not AF, Riva 2.5mg bid did not sig. red. primary MACE endpt or the 2dary comp. of CV death or rehosp for worsening HF. Sig. incr. major bld. Slide deck here: https://t.co/WnxIaxO53F #ESCCongress

CMichaelGibson's tweet photo. COMMANDER HF Trial: In pts w/ recent worsening HF w/ red. EF & CAD but not AF, Riva 2.5mg bid did not sig. red. primary MACE endpt or the 2dary comp. of CV death or rehosp for worsening HF. Sig. incr. major bld.

Slide deck here:
https://t.co/WnxIaxO53F

#ESCCongress https://t.co/Caw6AqCUzD

0

6

5

0

CardiacDevices retweeted

European Society of Cardiology

@escardio

almost 8 years ago

New algorithms on use of DAPT in ACD undergoing revascularisation. #ESCCongress #ESCGuidelines

0

108

79

5

0

CardiacDevices @CardiacDevices

almost 8 years ago

#cardiacdevices #ESCCongress https://t.co/TGVyr32uTC #HFpEF

0

1

0

CardiacDevices @CardiacDevices

almost 8 years ago

Keep your #money #omega3 in the current doses will not reduce #CVrisk

Healio @GoHealio

almost 8 years ago

“ASCEND is the largest & longest-duration of omega-3 fatty acid supplements ever. In this study we demonstrated no effect on the primary outcome of serious vascular events & no effect on cancer or total all-cause mortality" - Louise Bowman, MD #ESCCongress https://t.co/9zYicRW3HO

GoHealio's tweet photo. “ASCEND is the largest & longest-duration of omega-3 fatty acid supplements ever. In this study we demonstrated no effect on the primary outcome of serious vascular events & no effect on cancer or total all-cause mortality" - Louise Bowman, MD #ESCCongress https://t.co/9zYicRW3HO https://t.co/oE4s2d0j7i

0

2

0

CardiacDevices @CardiacDevices

almost 8 years ago

#SCOT-HEART #ESCCongress #itisnotsimple

John Mandrola, MD

@drjohnm

almost 8 years ago

The SCOT-HEART study reports that doing a CT scan in pts w/ chest pain reduces heart attack by 41%. And NEJM publishes it This, my friends, deserves serious critical appraisal>> https://t.co/MZf3EoKPns #ESCcongress #CardioTwitter #FOAMed Thx to @AndrewFoy82